Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells…
ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic resistance Combination was well-tolerated; supports…
Unlocking enterprise-wide, actionable insights can help to improve outcomes April 17, 2023 Amsterdam, the Netherlands and Chicago, USA – Royal…
New domestic supply source to help address critical shortage of medical radioisotopesProprietary platform will be capable of generating up to 12 different…
Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation…
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company…
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations In vivo characterization shows a…
Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosisFirst time efti…
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy…
IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930’s differentiated paralog…